サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：中枢神経系治療薬市場2022-2028
市場調査レポート
商品コード
1215776

中枢神経系治療薬市場2022-2028

Central Nervous System Therapeutic Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
中枢神経系治療薬市場2022-2028
出版日: 2023年01月20日
発行: Orion Market Research
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の中枢神経系治療薬市場は、予測期間中に7.5%のCAGRで成長すると予測されています。世界中で神経疾患の有病率が上昇していることが、中枢神経系治療薬の世界市場の成長率上昇につながっています。世界保健機関（WHO）によると、全世界で5,000万人以上の人々がてんかんを患っているとされています。また、認知症患者様の数は全世界で4,750万人、毎年770万人が新たに認知症に罹患していると推定されています。アルツハイマー型認知症は、認知症の最も一般的な原因であり、60～70%の症例に関与していると考えられています。また、片頭痛の有病率は全世界で10％を超えています。このことが、これらの疾患の治療に対する需要を加速させ、市場の成長を促進しています。

世界の中枢神経系治療薬市場は、適応症、用途、薬物クラスに基づいて区分されています。適応症に基づき、市場は神経血管疾患、中枢神経系外傷、メンタルヘルス、神経変性疾患、感染症、がんなどに分類されます。用途別では、病院・診療所、在宅医療、その他に分類されます。薬物クラスにより、市場は免疫調節薬、インターフェロン、脱炭酸酵素阻害薬、ドーパミン作動薬、抗うつ薬、その他に分類されます。上記の区分は、要件に応じてカスタマイズすることが可能です。免疫調節剤は、免疫系を抑制し、感染症やがん、その他の疾患と闘う身体をサポートするために使用されます。

目次

第1章 レポート概要

  • 現在の産業分析と成長性の展望
  • 中枢神経系治療薬の世界市場の回復シナリオ
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場の概要とインサイト

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • レコメンデーション
    • まとめ

第3章 競合情勢

  • 主要企業分析
    • Johnson & Johnson Services Inc.
    • Merck & Co. Inc.
    • Novartis AG
    • Biogen Inc.
    • Eli Lilly and Company Inc.
  • 主要戦略分析

第4章 市場セグメンテーション

  • 中枢神経系治療薬の世界市場：適応症別
    • 神経血管疾患
    • 中枢神経系外傷
    • メンタルヘルス
    • 神経変性疾患
    • 感染症
    • がん
  • 中枢神経系治療薬の世界市場：用途別
    • 病院と診療所
    • 在宅医療
    • その他
  • 中枢神経系治療薬の世界市場：薬物クラス別
    • 免疫調節薬
    • インターフェロン
    • デカルボキシラーゼ阻害剤
    • ドパミンアゴニスト
    • 抗うつ薬
    • その他

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • AstraZeneca plc
  • Cipla Ltd.
  • CNS Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Lupin Ltd.
  • Medopharm Private Ltd.
  • Neurelis, Inc.
  • Nuventra Pharma Sciences
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Shire plc
  • Teva Pharmaceutical Industries Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEUROVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CNS TRAUMA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR MENTAL HEALTH MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEURODEGENERATIVE DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOMECARE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 13. GLOBAL IMMUNOMODULATORY DRUGS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL INTERFERONS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBAL DECARBOXYLASE INHIBITORS CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 16. GLOBAL DOPAMINE AGONISTS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 17. GLOBAL ANTIDEPRESSANTS CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 18. GLOBAL OTHER DRUG CLASS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 19. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 20. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 21. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 22. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 23. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 24. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 25. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 26. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 27. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 28. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 29. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 30. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 31. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 32. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 33. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
  • 34. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 35. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)

 

LIST OF FIGURES

  • 1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEURODEGENERATIVE DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY INDICATION, 2021 VS 2028 (%)
  • 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEUROVASCULAR DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CNS TRAUMA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR MENTAL HEALTH MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEURODEGENERATIVE DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR INFECTIOUS DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOSPITAL & CLINIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOMECARE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR OTHERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY DRUG CLASS, 2021 VS 2028 (%)
  • 14. GLOBAL IMMUNOMODULATORY DRUGS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. GLOBAL INTERFERONS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 16. GLOBAL DECARBOXYLASE INHIBITORS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 17. GLOBAL DOPAMINE AGONISTS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 18. GLOBAL ANTIDEPRESSANTS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 19. GLOBAL OTHER DRUG CLASS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 20. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 21. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. UK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. REST OF EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 31. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 32. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 33. REST OF ASIA-PACIFIC CENTRAL NERVOUS SYSTEMTHERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 34. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026832

Title:Global Central Nervous System Therapeutic Market Size, Share and Trends Analysis Report, By Indication (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, and Cancer), By Application (Hospital and Clinic, Homecare, and Others), By Drug Class (Immunomodulatory Drugs, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Antidepressants, and Others), Forecast Period (2022-2028).

The global central nervous system therapeutics market is anticipated to grow at a CAGR of 7.5% during the forecast period. The rising prevalence of neurological disorders across the globe is leading to the increasing growth of the global central nervous system therapeutic market. According to the World Health Organization (WHO), over 50 million people have epilepsy globally. It is estimated that there are globally 47.5 million people with dementia with 7.7 million new cases every year. Alzheimer's disease is the most common cause of dementia and may contribute to 60-70% of cases. The prevalence of migraine is more than 10% across the globe. This, in turn, is accelerating the demand for the treatment of these conditions, thereby driving market growth.

The global central nervous system therapeutics market is segmented based on indication, application, and drug class. Based on the indication, the market is segmented into neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, and cancer. Based on the application, the market is segmented into hospitals & clinics, homecare, and others. Based on drug class, the market is segmented into immunomodulatory drugs, interferons, decarboxylase inhibitors, dopamine agonists, antidepressants, and others. The above-mentioned segments can be customized as per the requirements. Immunomodulatory drugs are used as it suppresses the immune system and supports the body to fight infection, cancer and other diseases.

The global central nervous system therapeutic market is segmented based on geography including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa and Latin America). The market can be analyzed for a particular region or country level as per the requirement. North American region is expected to hold a significant share in the global CNS therapeutic market, owing to the rising incidence of neurodegenerative disorders such as brain tumor in the region. According to the American Cancer Society, latest data in 2022 around 25,050 malignant tumors of the brain or spinal cord will be diagnosed in the US and around 18,280 people will die from the brain and spinal cord tumors.

The major companies serving the global central nervous system therapeutic market include Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Biogen Inc., and Eli Lilly, and Company Inc. The market players are contributing to the market growth through the adoption of various strategies including mergers and acquisitions, collaborations, and new product launches, to stay competitive in the market. For instance, in May 2022, Biogen Inc. and Denali Therapeutics Inc. announced the initiation of phase 2b study of LRRK2 Inhibitor in Parkinson's Disease which is a central nervous disease that will slow down the progression of Parkinson's disease.

Research Methodology

The market study of the global central nervous system therapeutic market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Central Nervous System Therapeutic Market Research and Analysis by Indication
  • Global Central Nervous System Therapeutic Market Research and Analysis by Application
  • Global Central Nervous System Therapeutic Market Research and Analysis by Drug Class

The Report Covers:

  • Comprehensive research methodology of the global central nervous system therapeutic market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global central nervous system therapeutic market.
  • Insights about market determinants that are stimulating the global central nervous system therapeutic market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Recovery Scenario of Global Central Nervous System Therapeutic Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Johnson & Johnson Services Inc.
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. Merck & Co. Inc.
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Novartis AG
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Biogen Inc.
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
    • 3.1.5. Eli Lilly and Company Inc.
      • 3.1.5.1. Overview
      • 3.1.5.2. Financial Analysis
      • 3.1.5.3. SWOT Analysis
      • 3.1.5.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Central Nervous System Therapeutics Market by Indication
    • 4.1.1. Neurovascular Diseases
    • 4.1.2. CNS Trauma
    • 4.1.3. Mental Health
    • 4.1.4. Neurodegenerative Diseases
    • 4.1.5. Infectious Diseases
    • 4.1.6. Cancer
  • 4.2. Global Central Nervous System Therapeutic Market by Application
    • 4.2.1. Hospitals and Clinics
    • 4.2.2. Homecare
    • 4.2.3. Others
  • 4.3. Global Central Nervous System Therapeutic Market by Drug Class
    • 4.3.1. Immunomodulatory Drugs
    • 4.3.2. Interferons
    • 4.3.3. Decarboxylase Inhibitors
    • 4.3.4. Dopamine Agonists
    • 4.3.5. Antidepressants
    • 4.3.6. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AstraZeneca plc
  • 6.2. Cipla Ltd.
  • 6.3. CNS Pharmaceuticals, Inc.
  • 6.4. F. Hoffmann-La Roche Ltd.
  • 6.5. GlaxoSmithKline plc
  • 6.6. H. Lundbeck A/S
  • 6.7. Lupin Ltd.
  • 6.8. Medopharm Private Ltd.
  • 6.9. Neurelis, Inc.
  • 6.10. Nuventra Pharma Sciences
  • 6.11. Otsuka Pharmaceutical Co., Ltd.
  • 6.12. Pfizer Inc.
  • 6.13. Sanofi S.A.
  • 6.14. Shire plc
  • 6.15. Teva Pharmaceutical Industries Ltd.